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1. Introduction
Drug delivery systems (DDSs) are pharmaceutical formulations or devices that help in achiev-
ing targeted delivery and/or controlled release (CR) of therapeutic agents in our body [1]. 
Following administration, the DDSs liberate the active ingredients, and subsequently, the bio-
active molecules are transported across various biological barriers to reach the site of action. 
The scientists have contributed substantially to understand the role of different physiological 
barriers in efficient transport of drugs in the circulatory system and drug movement through 
cells and tissues. In addition, their significant contribution to the development of a number 
of new modes of drug delivery has entered clinical practice. Despite a significant advance-
ment in the process of new drug design and discovery, many drugs have unacceptable side 
effects due to interaction of the drug with parts of the body that are not the target for the 
drug. Sometimes, side effects occur depending on the medication, the mode of delivery, and 
response from our body. The buildup of high blood plasma drug concentration due to accu-
mulation of drug from repeated administration of conventional DDS may lead to untoward 
side effects. Hence, the attempts must be made to afford better patient compliance effect from 
the reduction in the number and frequency of doses needed to maintain the desired therapeu-
tic responses. These side effects can vary greatly from person to person in type and severity. 
The method by which the drug is delivered can have a significant impact on its efficacy.
It is necessary to develop suitable DDS for all drugs to allow their effective and safe applica-
tion to the patient. Indeed, DDSs control the drug release rate and drug absorption and ulti-
mately the therapeutic effects along with side effects of the drug. Ideal DDSs ensure that the 
active drug is available at the site of action according to the need of patient for an intended 
duration. The drug concentration at the appropriate site should remain in the therapeutic 
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window, that is, between minimal effective concentration (MEC) and minimal toxic concen-
tration (MTC). This concept is illustrated in Figure 1.
The maintenance of drug concentration in therapeutic range depends on the frequency of 
 dosing, the drug clearance rates, the route of administration, and the DDS employed. Some 
drugs have an optimum concentration range within which maximum benefit is derived, and 
concentrations above or below this range can be toxic or produce no therapeutic benefit at all. 
DDS can be classified according to their physical state, site/route of  administration, and the rate 
of drug release. The dosage form may be gaseous (e.g., anesthetics), liquid (e.g., solutions, emul-
sions, and suspensions), semisolid (e.g., creams, ointments, and gels), and solid dosage (e.g., 
tablets and capsules) [2]. Drugs can be administered directly into the body through injection 
or infusion termed parenteral drug delivery. Depending on the site of  administration, one can 
differentiate among intravenous, intramuscular, subcutaneous, intradermal, and intraperito-
neal administration. Mostly semisolid dosage forms including creams, ointments, and gels are 
applied onto the skin to enter into the body. However, the liquid dosage forms, such as emul-
sions, or solid dosage forms, such as transdermal patches, can also be used. Dosage forms can 
be classified into immediate release (IR) and modified release (MR). IR dosage forms allow the 
drug to dissolve in the gastrointestinal contents, without delaying or prolonging the dissolution 
or absorption of the drug. In MR dosage forms, the time course and/or location of drug release 
is chosen to accomplish therapeutic or convenience objectives not offered by conventional dos-
age forms. MR dosage forms include both delayed and extended release drug products.
Figure 1. The drug plasma levels after single oral administration of a drug from (a) IR dosage form, (b) SR dosage form, 
and (c) CR dosage form.
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Delayed release dosage forms release the active ingredient at a time other than immedi-
ately after administration, for example, enteric-coated dosage forms or colon-specific dos-
age forms. These systems delay the release of drug until the dosage form reaches the small 
intestine. In this way, they can protect the drug from degradation in the low-pH environ-
ment of the stomach or protect the stomach from irritation by the drug. The dosage form is 
coated with polymer that dissolves and releases the drug at higher pH during its travel from 
 low-pH environment of the stomach to the high-pH environment of the small intestine. Once 
this occurs, the release is again immediate, and the resulting plasma concentration versus 
time curve is similar to the one for IR dosage forms. Extended release products (sustained 
release (SR) and controlled release systems) are formulated to make the drug available over 
an extended period after ingestion. This allows a reduction in dosing frequency compared to 
the drug presented as a conventional dosage form. IR dosage forms are designed to achieve 
quicker onset of drug action than that achieved by delayed or extended release dosage forms, 
which are often desirable to increase the stability, safety, and efficacy of the drug, to improve 
the therapeutic outcome of the drug treatment, and/or to increase patient compliance and 
convenience of administration.
The extended release DDS can be of either sustained release (SR) or controlled release (CR) 
dosage forms. The polymer-based matrix or reservoir sustained release systems maintain the 
rate of drug release over a longer period and reduce the frequency of dosing. Conversely, CR 
DDSs are designed to predict constant plasma drug concentrations regardless of the biological 
environment of the application site. Therefore, CR systems actually control the drug concentra-
tion in the body, whereas SR systems just regulate the release of the drug from the dosage form 
[3, 4]. Further, SR systems are basically restricted to oral formulations, while CR systems can be 
administered through various routes, including transdermal, oral, and vaginal administration.
Ideally, the release rate from the dosage form should be the rate-determining step for drug 
absorption and in fact for the drug concentration in the plasma and target site. The result-
ing plasma concentration versus time curves become increasingly flatter from IR to extended 
release dosage forms, indicating the prolonged maintenance of drug in the therapeutic range 
after a single administration of the dosage form. Controlled DDSs have been introduced to 
overwhelm the drawback of fluctuating drug levels associated with conventional dosage 
forms [5]. Controlled drug release and subsequent biodegradation are important for develop-
ing successful formulations. The release mechanisms involve desorption of surface-bound/
adsorbed drugs; diffusion through the carrier matrix or polymer membrane surrounding 
drug core; matrix erosion; combination of erosion/diffusion process; and responsiveness to 
stimuli such as light, changes in pH, or temperature.
The formulation scientist must optimize the bioavailability of the drug. To achieve this goal, 
the delivery systems should allow the drug to reach the systemic circulation, more  importantly 
to the target site in the body to avoid side effects by preventing the exposure of drug to the 
nontarget sites. In addition, the drug must be physically and chemically compatible with 
the formulation excipients in the dosage forms and stable microbiologically. The delivery 
 systems should be designed in such a way that it can improve the patient compliance. One 
can design an oral dosage form instead of parenteral formulations for the drug, which can 
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allow self-administration of the dosage forms. Moreover, the pharmaceutical quality of the 
delivery systems must be ensured in accordance with the regulatory specifications to facilitate 
reproducible drug release from the system and minimize the influence of the body such as 
food effects on drug release. It is also necessary to investigate the feasibility of the developed 
DDS to be scaled up from the laboratory to the production scale.
However, controlled release systems do not exclusively deliver the drug to the target organ. 
For this reason, the target-specific drug delivery systems must be designed in order to control 
biodistribution of the drug. Consequently, various novel concepts have been emerged to meet 
the specific needs of an ideal drug delivery system. This chapter introduces a brief description 
of targeted drug delivery mechanism along with some of the novel-targeted drug delivery 
options.
2. Targeted drug delivery
Very few drugs bind selectively to the desired therapeutic target, and hence, some target-
ing approaches are required to destine the drug in desired tissue or organ to reduce efficacy 
and dose-related toxicity. The concept of targeted drugs is not new, but dates back to 1960 
when Paul Ehrlich first postulated the concept of “magic bullet,” and this continues to be a 
challenge to implement in the clinic. The challenges include the selection of proper target 
for a particular disease, drug for effective treatment and stable, biodegradable drug carriers 
while avoiding the immunogenic and nonspecific interactions that efficiently clear foreign 
material from the body. Moreover, the preparation of the delivery system should be easy 
or reasonably simple, reproductive, and cost-effective. Nanoparticles (NPs) are potentially 
useful as  carriers of active drugs and, when coupled with targeting ligands, may fulfill many 
attributes of a “magic bullet.” Furthermore, the NPs offer several potential advantages includ-
ing increased efficacy and therapeutic index, improved pharmacokinetic effect, reproducible 
sizes with opportunity for surface functionalization, ability to entrap both hydrophilic and 
lipophilic drug, increasing stability of drug from enzymatic degradation, thereby delivering 
entrapped drug intact to various tissue and cells for site-specific and targeted delivery and 
thus  decreasing drug toxicity. The size and other characteristics can be manipulated depend-
ing on the drug and intended use of the product [6]. The drug targeting strategies must meet 
two basic requirements to achieve effective drug delivery. The drugs should reach the desired 
sites after administration, with minimal loss of the dose and activity in blood circulation. 
Second, the drugs should act only on target cells without harmful effects to healthy tissue 
[7]. Two  strategies have been adopted for drug targeting: passive targeting and active targeting.
2.1. Passive targeting
Passive targeting exploits natural conditions of the target organ or tissue to direct the drug to 
the target site. For example, passive targeting takes advantage of the unique pathophysiologi-
cal characteristics of tumor vessels, that is, leaky vasculature with 100–800 nm pores enabling 
nanodrugs to accumulate in tumor tissues. Typically, tumor vessels are highly disorganized 
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and dilated with a high number of pores, resulting in enlarged gap junctions between endo-
thelial cells and compromised lymphatic drainage. The leaky vascularization, coupled with 
poor lymphatic drainage, serves to enhance the permeation and retention of NPs within the 
tumor region. This is often called enhanced permeability and retention (EPR) effect [8]. The 
drug-loaded NPs are preferentially accumulated in tumor tissue than normal cells, solely 
due to their small particle size rather than binding. The NPs cannot readily cross the blood 
capillaries of normal tissues because they are held up with tight junctions. Therefore, passive 
targeting approach can assist in depositing a higher amount of drug in solid tumors than that 
of free drug.
In addition to the EPR effect, the passive targeting is supported by microenvironment sur-
rounding tumor tissue that is different from that of healthy cells. The fast-growing tumor cells 
require more oxygen and nutrients to maintain high metabolic rate. Consequently, glycolysis 
is stimulated to acquire more energy and creates an acidic environment [9]. This advantage 
can be exploited to target chemotherapeutic agents to the tumor cells. The pH-sensitive NPs 
have been prepared that remain stable at physiological pH 7.4 but degrade at the acidic pH 
of the tumor and liberate the drug molecules. In case of cancer treatment, the size and surface 
properties of drug delivery NPs must be controlled specifically to avoid uptake by the reticu-
loendothelial system (RES) to maximize circulation times and targeting ability [10].
2.2. Active targeting
One way to overcome the limitations of passive targeting is to attach ligands such as antibod-
ies, peptides, vitamins, aptamers, or small molecules by a variety of conjugation chemistries to 
the surface of the nanocarriers that only bind to specific receptors on the cell surface [11]. For 
high specificity, however, the receptors need to be highly expressed on tumor cells rather than 
on normal cells. The targeting conjugates are internalized by receptor-mediated endocytosis 
mechanism. The targeting ligands bind with the receptors first, followed by endosome forma-
tion with the enclosure of the ligand-receptor complex by plasma membrane. The endosome 
is then transferred to specific organelles, and drugs are released by acidic pH or enzymes.
3. Novel delivery modalities
To prevent chemical degradation, harmful side effects, and improve drug bioavailability 
and accumulation in the desired site, various drug delivery and drug targeting systems 
are currently under development. The delivery carriers can be made slowly degradable, 
 stimuli-responsive (e.g., pH, ionic strength, temperature, ultrasound, light, electricity, 
enzymes), and even targeted (e.g., by conjugating them with specific ligands). Over last two 
decades, nanotechnology has shown potential benefits in improving drug delivery and tar-
geting properties and therefore opens up new markets for pharmaceutical and drug delivery 
companies. The drug delivery systems are also designed to overcome some physical barriers, 
such as the blood-brain barrier (BBB) for better location and effectiveness of the drug at the 
target site. Due to their small size, the NPs can pass through certain biological barriers.
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Polymeric NPs are colloidal particles with a size range of 10–1000 nm, which are fabricated 
using biodegradable synthetic polymers, such as poly (lactide-co-glycolide), polyacrylates, 
and polycaprolactones; nonbiodegradable synthetic polymers, such as poly (methyl methac-
rylate), polyacrylamide, poly (vinyl alcohol), and poly (ethylene glycol); or natural polymers, 
such as albumin, gelatin, alginate, gellan gum, and chitosan [12]. Sometimes, blends or graft 
copolymers of natural and synthetic polymers are also used. In recent years, biodegradable 
polymeric NPs have attracted considerable attention in the fabrication of potential drug deliv-
ery devices due to easy removal of degraded fragments from the body via normal metabolic 
pathways.
Various methods, such as solvent evaporation, spontaneous emulsification, solvent diffusion, 
salting out/emulsification-diffusion, and polymerization, have been used to prepare the NPs 
[13]. Depending upon the method of preparation of NPs, the drug is confined to a cavity sur-
rounded by a polymer membrane (nanocapsules) or dispersed physically and uniformly in 
the polymer matrix (nanospheres). The drug is loaded via hydrophobic interactions between 
drugs and nanocarriers. The drug can also be conjugated to polymeric carriers via covalent 
chemistry.
An important feature of targeted particle delivery system is the ability to simultaneously 
carry a high amount of drug while displaying ligands on the surface of particles. The overall 
binding strength of NPs to target is a function of both the affinity of the ligand-target interac-
tion and the number of targeting ligands present on the particle surface [14].
The drug-loaded particles are internalized into cells in determining their biological activity. The 
particles of as large as 500 nm size can be internalized by nonphagocytic cells via  energy-dependent 
process. The particles with <200 nm diameter are internalized via clathrin-coated pits, but larger 
ones are taken up by cells via caveolae membrane invaginations [15]. However, the internal-
ization of particles can be mediated independent of both clathrin and caveolae pathways. To 
facilitate efficient internalization, NPs have been targeted against  internalizing  receptors, and an 
increased therapeutic activity has been observed in some tumor models [16, 17].
Targeting ligands include any molecule that recognizes and binds to target antigen or receptors 
overexpressed or selectively expressed by particular cells or tissue components. The antibodies 
or their fragments, peptides, glycoproteins, vitamins, or carbohydrates are the common class of 
ligands. The NPs are made long circulating by making their surface  hydrophilic after coupling 
or coating poly(ethylene glycol) (PEG). Functionality could also be introduced by incorporat-
ing PEG with functional end groups for coupling to target ligands.
There has been a considerable progress in the field of gene delivery using polymeric NPs. For 
gene delivery, the plasmid DNA is introduced into the target cells, and the genetic informa-
tion is ultimately translated into the corresponding protein [18]. To achieve this, an efficient 
vector that possesses high transfection efficiency, biodegradability, targeting ability, DNA 
protecting ability, stimuli sensitivity, and low cytotoxicity for delivering a target gene to spe-
cific tissues or cells must be selected to cure both the genetic and acquired diseases of human 
[19]. Despite more gene transfection efficiency, viral vectors may pose a significant risk to 
patients, while nonviral carriers are inherently safer than viral carriers [20]. Furthermore, 
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the nonviral carriers are expected to be less immunogenic with a possible versatile surface 
modification [21]. The nonviral vectors are usually made of lipids or polymers with/without 
using other inorganic materials. The NPs can protect genes against nuclease degradation and 
improve their stability [22]. Furthermore, they can be used for targeted delivery purpose. 
Because the biopolymers are non-toxic, biodegradable, and biocompatible, the biopolymer-
based non-viral vectors are also being tested for safe and efficient gene delivery.
The liposomes are the most clinically established nanosystems for drug delivery. They are 
self-assembled spherical vesicles of bilayer structures of phospholipids and cholesterol sur-
rounding an aqueous core, and their size can be controlled as small as 50–100 nm. The vesicles 
are biocompatible and biodegradable and confer the ability to entrap both hydrophilic and 
hydrophobic drugs. The variation in composition of lipid membrane and surface chemistry, the 
liposome properties, such as size, surface charge, and functionality can be easily manipulated. 
The incorporation of polyethylene glycol (PEG) prevents interactions with plasma proteins, 
retards recognition by the RES [23], and thus enhances the liposome circulation lifetime, that 
is, stealth liposomes. Liposomes can also be conjugated with active-targeting ligands, such as 
antibodies or folate for target-specific drug delivery. Their efficacy has been demonstrated in 
reducing systemic effects and toxicity, as well as in attenuating drug clearance [24]. Despite 
potential advantages, the liposomes as targeted drug delivery carriers are associated with some 
major drawbacks like poor control over drug release rate, leakage of drug into the blood, low 
encapsulation efficiency, industrial scale-up, and poor storage stability [25, 26].
Recently, extensive work and experiments with solid lipids resulted in the invention of 
 lipid-based solid particles in the submicron range (10–1000 nm). These NPs are made up of bio-
compatible and biodegradable lipids with potential application in drug delivery. They  possess 
a solid lipid core matrix that can solubilize lipophilic molecules for enhancing bioavailability. 
The physiologically similar lipid core of triglycerides or fatty acids or waxes is stabilized by 
 surfactants (emulsifiers). All classes of emulsifiers (with respect to charge and  molecular weight) 
can be used to stabilize the lipid dispersion. It has been found that an emulsifier combination 
may prevent particle agglomeration more efficiently [27]. The lipid NPs combine the advantages 
of lipid emulsion and polymeric NPs while overcoming the temporal and in vivo stability issues 
that trouble the conventional and nanoscale delivery approaches [28]. A variety of materials can 
be used to engineer solid NPs for targeting tissues by either passive or active targeting.
Lipid-polymer hybrid NPs are core-shell structures comprising polymer cores and lipid 
shells, which exhibit complementary characteristics of both polymeric NPs and liposomes, 
particularly in terms of their physical stability, biocompatibility, and in vivo cellular delivery 
efficacy [29]. In core-shell-type lipid-polymer hybrid NPs, a biodegradable polymeric core is 
surrounded by a shell composed of phospholipid layers. The hybrid architecture can provide 
advantages such as controllable particle size, surface functionality, high loading of multiple 
drugs, tunable drug release profile, and good serum stability [30].
Several drugs do not have adequate physiochemical characteristics such as high lipid solubility, 
low molecular size, and positive charge, to traverse blood-brain barrier and deliver drug into 
the brain [31]. Therefore, the delivery of drugs to central nervous system (CNS) is a challenge 
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for treating neurological disorders. The drugs may be administered directly into the CNS or 
administered systematically for targeted action in the CNS. The osmotic and chemical open-
ing of the blood-brain barrier as well as the transport/carrier systems constitutes some of the 
widely reported strategies to promote the permeation of blood-brain barrier (BBB) and delivery 
of drugs in brain. In conjunction with the net delivery of drug, the access to the intended  target 
site within the CNS is also important. To serve this purpose, the drugs may be conjugated 
with various nanostructures such as liposomes and NPs and a suitable route of administration 
can be sought. It has been postulated that nanoscale drug carriers possess a great potential for 
improving the delivery of drugs through nasal routes to deliver drugs to the brain. Among 
other mucosal sites, nasal delivery is especially attractive for brain-targeted drug delivery, as 
the nasal epithelium is characterized by its relatively high permeability, vuscularized mucosa, 
and low enzymatic activity. If a nasal drug formulation is delivered deep and high enough into 
the nasal cavity, the olfactory mucosa may be reached and drug transport into the brain and/or 
cerebrospinal fluid (CSF) via the olfactory receptor neurons may occur [32].
Transdermal systems in the form of patches deliver the drugs across the skin barrier for 
systemic effects at a predetermined and controlled rate. Due to concentration gradient 
between the transdermal patch and blood, the drug will continue diffusing into the blood 
for prolonged period of time and maintain constant drug concentration in the blood flow. 
Transdermal drug delivery avoids problems such as gastrointestinal irritation, metabolism, 
pH-dependent variation in delivery rate, and interference with gastric emptying due to pres-
ence of food. However, slow penetration rates, lack of dosage flexibility and/or precision, and 
a restriction to relatively low dosage drugs are the major limitations. The stratum corneum of 
the skin forms a formidable barrier against uptake, and thus transdermal delivery is difficult 
to achieve. The substances having molecular weight greater than 500 Da [33] and hydrophilic 
characteristics encounter the difficulty in absorption through skin. Penetration enhancers 
often have to be added to the delivery system to improve delivery into or through the skin. 
Recently, it has been demonstrated that atmospheric-pressure argon microplasma irradiation 
(AAMI) can improve skin permeability of drugs without the need of injection needles and 
skin damages [34]. AAMI can be a promising alternative to promote drug delivery through 
the skin and simultaneously minimize the pain from other manipulations related to skin 
 penetration enhancement. However, the feasibility of atmospheric microplasma irradiation is 
still under investigation for enhancing percutaneous absorption of drugs.
The delivery of drug to a specific target in the body is comparable to the magic bullet principle 
applied in nuclear medicine. Nuclear medicine may advance drug development by visual-
izing biodistribution and site of action [35]. The biodistribution and release kinetics of drug 
from the novel formulations can be quantified by radiolabeling with γ-emitting radionuclide. 
Many nuclear medicine departments have participated in the assessment of drug perfor-
mance and toxicity in contributing data to clinical trials. The application of nuclear medicine 
techniques to the evaluation of pharmaceutical formulations has been an interesting area of 
work. Scintigraphy can be used to determine the position of drug release and assess site-spe-
cific absorption of orally administered drugs, for example, the evaluation of controlled release 
formulation designed to release the drug specifically in colon [36]. Hence, the importance of 
nuclear medicine in drug delivery application has been described in detail in this book.
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4. Future considerations
The new delivery methods could enhance the performance of drugs by increasing 
effectiveness, safety, and patient compliance and ultimately reduce healthcare costs. 
Nanotechnology could be strategically implemented in developing new drug delivery 
systems that can expand drug markets. Nanomaterials are poised to take advantage of 
existing cellular machinery to facilitate the delivery of drugs. However, clinical develop-
ment of drugs is halted because of poor biopharmaceutical and undesirable pharmacoki-
netic properties. Novel delivery technologies are being tested for overcoming the barriers 
toward safe delivery of drugs. An in-depth understanding of novel strategies constitutes 
the primary focus and subsequent demonstration of easy scale-up of the formulations with 
favorable pharmacokinetics and toxicity profiles could augment the translation of research 
findings into practical therapeutics. A collaborative effort among scientists in various dis-
ciplines, including medicine, materials science, engineering, physics, and biotechnology 
could potentiate the translation of novel laboratory innovation into commercially viable 
medical products.
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